论文信息 - A phase Ib/II study of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus anlotinib as first-line treatment in patients with advanced non-small cell lung cancer. - 字舞流文

A phase Ib/II study of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus anlotinib as first-line treatment in patients with advanced non-small cell lung cancer.

Baiyong Li | Lin Wu | Bolin Chen | Xingya Li | Hui-juan Wang | W. Yao | Yu Xia | Qianzhi Wang | X. Pu | Yan Xu | Jia Li | Y. Kong | F. Xu | Ze-min Xiao | Kang Li | Yingying Du | Qian Chu | Li Xu | Gen Lin | Jie Lin | Hong Sun | Hailong Liu | Huaxin Duan | Liyu Liu